Amendments to the Claims:

Please cancel claims 3, 10-18, 20, and 28-30 without disclaimer or prejudice to applicants' right to pursue the subject matters of these claims in the future.

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating a fibrosis-related pathology in a subject which comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a Phospholipase D3 inhibitor so as to thereby treat the subject.

2. (Currently Amended) The method of claim 1 wherein the pharmaceutical composition comprises an oligoribonucleotide or oligonucleotide which down-regulates the expression of gene Phospholipase D3 by at least 50% as compared to a control.

3. (Canceled)

4. (Currently Amended) The method of claim 1 wherein the Phospholipase D3 inhibitor is an antisense oligonucleotide.

5. (Currently Amended) The method of claim 1 wherein the Phospholipase D3 inhibitor is a Phospholipase D3 siRNA.

6. (Currently Amended) The method of claim 1 wherein the Phospholipase D3 inhibitor is an expression vector comprising a nucleic acid molecule encoding Phospholipase D3 siRNA.

7. (Currently Amended) The method of claim 1 wherein the Phospholipase D3 inhibitor is an antibody which binds specifically to Phospholipase D3 polypeptide.

8. (Currently Amended) The method of claim 1 wherein the fibrosis-related pathology is chronic renal insufficiency, chronic renal insufficiency, nephropathy, liver fibrosis, cardiac fibrosis or kidney fibrosis.

9. (Original) The method of claim 1 wherein the fibrosis-related pathology is ocular scarring or cataract.

10-18. (Canceled)

19. (Currently Amended) A pharmaceutical composition for the treatment of fibrosis comprising as an active ingredient a Phospholipase D3 inhibitor together with a pharmaceutically acceptable carrier.

20. (Canceled)

21. (Currently Amended) The pharmaceutical composition of claim 19 wherein the Phospholipase D3 inhibitor is an oligoribonucleotide or oligonucleotide which down-regulates the expression of gene Phospholipase D3 by at least 50% as compared to a control.

22. (Currently Amended) The pharmaceutical composition of claim 19 wherein the Phospholipase D3 inhibitor is an antisense oligonucleotide.

23. (Currently Amended) The pharmaceutical composition of claim 19 wherein the Phospholipase D3 inhibitor is a Phospholipase D3 siRNA.

24. (Currently Amended) The pharmaceutical composition of claim 19 wherein the Phospholipase D3 inhibitor is an expression vector comprising a nucleic acid molecule encoding Phospholipase D3 siRNA.

25. (Currently Amended) The pharmaceutical composition of claim 19 wherein the Phospholipase D3 inhibitor is an antibody which binds specifically to Phospholipase D3 polypeptide.

26. (Currently Amended) The pharmaceutical composition of claim 19 wherein the fibrosis-related pathology is chronic renal insufficiency, chronic renal insufficiency, nephropathy, liver fibrosis, cardiac fibrosis or kidney fibrosis.

27. (Original) The pharmaceutical composition of claim 19 wherein the fibrosis-related pathology is ocular scarring or cataract.

28-30. (Canceled)